Epithelioid
RhoA and vigilin are candidates for immunohistochemical markers for epithelioid malignant mesothelioma
Scientific Reports 2022 November 2 [Link] Takuya Hiratsuka, Takushi Yamamoto, Akihiko Yoshizawa, Shinya Toyokuni, Tatsuaki Tsuruyama Abstract Diagnostic markers of malignant mesothelioma (MM) have been extensively investigated. Immunohistochemistry (IHC) markers, such as calretinin, have been used for pathologic diagnosis. However, more diagnostic markers are required to improve the specificity and sensitivity of pathologic diagnosis. This…
Read MoreFinal results of DIADEM, a phase II study to investigate the efficacy and safety of durvalumab in advanced pretreated malignant pleural mesothelioma
ESMO Open 2022 December 1 [Link] S Canova, G L Ceresoli, F Grosso, P A Zucali, F Gelsomino, G Pasello, M Mencoboni, E Rulli, F Galli, I De Simone, L Carlucci, A De Angelis, M Belletti, M Bonomi, A D’Aveni, M Perrino, F Bono, D L Cortinovis, DIADEM groupD Abstract Background: Malignant pleural mesothelioma (MPM)…
Read MoreFactors affecting the life expectancy in malignant pleural mesothelioma: Our 10 years of studies and experience
Medicine 2022 September 30 [Link] Filiz Cimen, Yetkin Agackiran, Sevim Düzgün, Melike Aloglu, Aysegül Senturk, Sükran Atikcan Abstract Malignant pleural mesothelioma (MPM) is an aggressive tumor with a poor prognosis. In our study, we aimed to investigate the specific clinical, laboratory, and radiological features of the tumor and the prognostic effect of SUVmax (maximum standardized…
Read MoreButein-instigated miR-186-5p-dependent modulation of TWIST1 affects resistance to cisplatin and bioenergetics of Malignant Pleural Mesothelioma cells
Cancer Drug Resistance 2022 July 3 [Link] Mario Cioce, Daniela Rutigliano, Annamaria Puglielli, Vito Michele Fazio Abstract Aim: Malignant pleural mesothelioma is a chemoresistant tumor, and biphasic and sarcomatoid histologies portend the worst prognosis for malignant pleural mesothelioma (MPM) patients. We obtained the microRNA expression profile of three biphasic-sarcomatoid MPM cell lines to identify commonly…
Read MoreDefine the Two Molecular Subtypes of Epithelioid Malignant Pleural Mesothelioma
Cells 2022 September 19 [Link] Umair Ali Khan Saddozai, Fengling Wang, Saadullah Khattak, Muhammad Usman Akbar, Muhammad Badar, Nazeer Hussain Khan, Lu Zhang, Wan Zhu, Longxiang Xie, Yongqiang Li, Xinying Ji, Xiangqian Guo Abstract Malignant pleural mesothelioma (MPM) is a fatal disease of respiratory system. Despite the availability of invasive biomarkers with promising results, there…
Read MoreExpression of phosphorylated ribosomal protein S6 in mesothelioma patients – correlation with clinico-pathological characteristics and outcome: results from the European Thoracic Oncology Platform (ETOP) Mesoscape project
Modern Pathology 2022 September 17 [Link] Jan Hendrik Rüschoff, Martina Haberecker, Zoi Tsourti, Kristiaan Nackaerts, Marc de Perrot, Luka Brcic, Ernest Nadal, Sotirios Tsimpoukis, Steven G Gray, Luca Ampollini, Joachim G Aerts, Emanuela Felley-Bosco, Michaela B Kirschner, Kim Monkhorst, Birgit Weynand, Fatemeh Bavaghar-Zaeimi, Miroslav Samarzija, Roger Llatjos, Stephen P Finn, Enrico Silini, Jan von der…
Read MoreFeasibility and safety of extended pleurectomy/decortication for malignant pleural mesothelioma. A single group experience
Thoracic Cancer 2022 September 2 [Link] Francesco Falanga, Pietro Rinaldi, Cristiano Primiceri, Chandra Bortolotto, Olga Oneta, Francesco Agustoni, Patrizia Morbini, Laura Saracino, Dimitrios Eleftheriou, Federico Sottotetti, Giulia Maria Stella Abstract Surgery is part of a multimodal therapeutic approach to malignant pleural mesothelioma (MPM) although its real beneficial effect is still controversial. The optimal precise sequence…
Read MorePSO-Based Evolutionary Approach to Optimize Head and Neck Biomedical Image to Detect Mesothelioma Cancer
Biomed Research International 2022 August 5 [Link] Sheeba Praveen, Neha Tyagi, Bhagwant Singh, Girija Rani Karetla, Meenakshi Anurag Thalor, Kapil Joshi, Melkamu Tsegaye Abstract Mesothelioma is a form of cancer that is aggressive and fatal. It is a thin layer of tissue that covers the majority of the patient’s internal organs. The treatments are available;…
Read MoreHypothesis: HEG1 and claudin-4 staining will allow a diagnosis of epithelioid and biphasic mesothelioma versus non-small-cell lung carcinoma with only two stains in most cases
Histopathology 2022 August 25 [Link] Andrew Churg, Julia R Naso Abstract Separation of mesothelioma from metastatic carcinoma requires immunohistochemical support, with small batteries of stains recommended as a starting-point, but these numbers commonly expand to 10, 12 or more stains, a process that is not only expensive but frequently generates anomalous or confounding results, leading…
Read MoreFDG PET/CT for Staging and Restaging Malignant Mesothelioma
Seminars in Nuclear Medicine 2022 August 11 [Link] Egesta Lopci, Angelo Castello, Luigi Mansi Abstract Malignant mesothelioma is an aggressive tumor originating from the mesothelial cells and presenting in general with a very poor prognosis. The pleural localization represents the prevailing disease site, while peritoneal involvement is commonly rare. The WHO classifies mesotheliomas into epithelioid,…
Read More